What is liothyronine (synthetic triiodothyronine) and how is it used in thyroid hormone replacement therapy?

What is Liothyronine?

Liothyronine is synthetic triiodothyronine (T3), the active thyroid hormone that directly acts on target tissues, available as liothyronine sodium for oral administration in hypothyroidism treatment. 1

Chemical Structure and Formulation

Liothyronine sodium (L-triiodothyronine or LT3) is a synthetic form of the natural thyroid hormone T3, which contains three iodine atoms and is formed by coupling one molecule of diiodotyrosine (DIT) with one molecule of monoiodotyrosine (MIT). 1 The medication is available in tablets of 5 mcg, 25 mcg, and 50 mcg strengths, with 25 mcg of liothyronine being equivalent to approximately 1 grain of desiccated thyroid or 0.1 mg of levothyroxine (T4). 1

Pharmacokinetics and Mechanism of Action

Liothyronine has rapid onset and short duration of action compared to levothyroxine, with distinct pharmacokinetic properties that influence its clinical use. 1

• Absorption: T3 is almost totally absorbed, with 95% absorption occurring within 4 hours. 1
• Protein binding: Unlike T4, liothyronine is not firmly bound to serum proteins, making it readily available to body tissues. 1
• Onset of action: Activity begins within a few hours, with maximum pharmacologic response occurring within 2-3 days. 1
• Half-life: The biological half-life is approximately 2.5 days, significantly shorter than levothyroxine's 7-day half-life. 1
• Mechanism: Thyroid hormones enhance oxygen consumption by most tissues, increase basal metabolic rate, and affect metabolism of carbohydrates, lipids, and proteins, with particular importance in central nervous system development. 1

Clinical Role in Thyroid Hormone Replacement

Levothyroxine (T4) monotherapy remains the standard of care for hypothyroidism, with liothyronine reserved for specific clinical scenarios. 2

Standard Treatment Approach

• First-line therapy: Oral T4 monotherapy (levothyroxine sodium) is the principal treatment for hypothyroidism. 2
• Levothyroxine dosing: For patients without risk factors (under 70 years, not frail, without cardiac disease), full replacement is approximately 1.6 mcg/kg/day using ideal body weight. 3
• Elderly/frail patients: Start with lower doses of 25-50 mcg and titrate up gradually. 3

Rationale for Combination Therapy Consideration

A subset of hypothyroid patients report persistent symptoms despite normalized TSH on levothyroxine monotherapy, which has generated interest in T4/T3 combination therapy. 4, 5

• Symptom persistence: Patients may experience ongoing fatigue, depression, and cognitive difficulties despite TSH normalization on levothyroxine alone. 4, 6
• Physiological basis: Levothyroxine is essentially a prodrug for T3, and T4 monotherapy may not restore physiological tissue levels of thyroid hormones, particularly T3. 7
• Genetic factors: Deiodinase polymorphisms (e.g., DIO2 Thr92Ala) may impair peripheral T4-to-T3 conversion in certain individuals. 4

Current Guideline Recommendations

Guidelines support levothyroxine monotherapy as standard, but allow for individualized trials of combination therapy in specific circumstances. 5, 6

• Primary recommendation: Levothyroxine alone should remain the treatment of choice for hypothyroidism. 8
• Trial criteria: For patients with confirmed overt hypothyroidism and persistent symptoms after adequate levothyroxine treatment (TSH 0.3-2.0 mU/L for 3-6 months) with excluded comorbidities, a trial of liothyronine/levothyroxine combined therapy may be warranted. 5
• Shared decision-making: The decision to start liothyronine should involve shared decision-making between patient and clinician. 5, 6

Evidence Base Limitations

Randomized controlled trials have not consistently demonstrated superiority of combination therapy over levothyroxine monotherapy. 9, 8

• Trial results: More than 15 clinical trials over two decades have failed to show consistent clinical benefit of LT4+T3 combinations. 9, 5, 8
• Patient preference: Some studies show patients prefer levothyroxine plus liothyronine combinations, though objective outcome measures remain equivocal. 8, 6
• Safety profile: Randomized trials and real-world pharmacovigilance data have not raised clear or consistent safety concerns with LT4+T3 treatment. 9

Safety Considerations

The rapid onset and offset of liothyronine activity allows for quick dosage adjustment but requires careful monitoring to avoid overtreatment. 1

• Cardiovascular risks: Potential adverse effects include angina, arrhythmia, and increased cardiac wall thickness, particularly with overtreatment. 2
• Bone health: Long-term overdosing may increase risk for osteoporosis and fractures. 2
• Monitoring advantage: The rapid cutoff of activity permits quick dosage adjustment and facilitates control of overdosage effects. 1

Special Clinical Contexts

Immune Checkpoint Inhibitor-Related Hypothyroidism

• Monitoring: TSH with optional FT4 can be checked every 4-6 weeks for asymptomatic patients on immune checkpoint inhibitor therapy. 3
• T3 measurement: T3 can be helpful in highly symptomatic patients with minimal FT4 elevations during thyrotoxicosis evaluation. 3

Myxedema Coma

• Emergency management: Inpatient endocrinology consultation can assist with IV levothyroxine dosing; if uncertainty exists about primary versus central hypothyroidism, hydrocortisone should be given before thyroid hormone is initiated. 3